NEUROSCIENCE MEETING: Statin Drugs May Lead To Lower Alzheimer’s Rate
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




NEUROSCIENCE MEETING: Statin Drugs May Lead To Lower Alzheimer’s Rate

KENSINGTON, MD. -- October 26, 1999 -- Nymox Pharmaceutical Corp. today announced that a method for treating Alzheimer’s Disease to which it has certain rights has shown promise in early studies conducted by Dr. Ben Wolozin, M.D., Ph.D., of the Loyola University Medical Center in Chicago, IL. Dr. Wolozin has licensed the commercial rights to his discoveries in this area to Nymox.

Dr. Wolozin presented the results of a study tracking the rates of Alzheimer’s Disease among some 50,000 patients at three major U.S. medical centers at the annual meeting of the Society for Neuroscience in Miami Beach, FL, on October 24, 1999.

"We found that the rate of Alzheimer’s Disease for patients taking two kinds of a type of an anti-cholesterol known as statin-lovastatin (Mevacor) and pravastatin (Pravachol) -- was reduced by 60 percent to 73 percent compared to a total patient population or compared to patients taking other medications typically used to treat cardiovascular disease or hypertension," said Dr. Wolozin. "Our studies suggests that these two drugs may protect against Alzheimer’s Disease."

Dr. Michael Munzar, M.D., medical director of Nymox, said that "while these findings need to be further verified, they might offer a potentially new and exciting approach to the treatment of this dread disease, which is now the fourth-leading cause of death among the elderly in the U.S.

"This appears to be the first time that a statin drug has been demonstrated in a large study to be associated with reduced Alzheimer’s Disease incidence. The reduction in the rate of Alzheimer’s Disease among the patients taking these two drugs is greater than other proposed therapeutics for the disease investigated to date. An additional positive feature is that these drugs are FDA approved, in common medical use, and well-tolerated by patients," Dr. Munzar added.

Related Links: statin-lovastatin (Mevacor), pravastatin (Pravachol) and Nymox Pharmaceutical Corp.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities